Because death after acute systemic vasculitis is now disease. More damage occurred after presentation than after relapse. Lung and multi-system damage uncommon, alternative measures of outcome are required. A significant component of patient morwere early indicators of poor outcome in severe non-fatal disease. Damage occurs early in systemic bidity is disease-related damage, which can be quantified by the Vasculitis Damage Index (64 items in vasculitis, and is an indicator of poor outcome. This novel observation, together with evidence of persist-11 organ-based systems). We investigated serially the time-course of damage in 120 patients with ent subclinical disease activity and the high frequency of relapse, suggests a need for new treatment systemic vasculitis, to determine the earliest indicators of outcome. High damage scores at 2 years strategies. Analogy with the management of acute leukaemia suggests a strategy of early diagnosis and after presentation were characteristic of fatal disease (OR 8.1-12.4). Significant damage occurred within intensive induction of remission, with early escalation of treatment for resistant disease. 6 months of presentation, and was a feature of fatal
Introduction
The dramatic increase in survival in systemic vasculitis to disease or drug toxicity occurs in the majority of patients with systemic vasculitis, despite remission of since the advent of cytotoxic therapy1-3 has significantly reduced the value of mortality as an index of active disease.7 Damage represents the accumulation of permanent scars due to disease or drug toxicity, outcome. Alternative measures of outcome address patient morbidity including disease activity, diseaseand to quantify, this we developed and validated the Vasculitis Damage Index (VDI).8 related damage and functional outcome.4 Disease activity can be measured using the Birmingham
The VDI is a powerful clinical tool which is comprehensive, credible, and more sensitive for Vasculitis Activity Score, which is a powerful clinical tool for guiding active treatment in systemic vasculitis. 5 recording the accumulation of damage in systemic vasculitis than other available indices. 8 We applied More than half the patients with systemic vasculitis suffer a relapse within 5 years of remission,6 and the VDI in a cross-sectional study to examine systemic vasculitis from the novel perspective of damage active or 'grumbling' disease can account for half the patient years of follow-up.7 Significant morbidity due in order to determine its relevance. For this purpose, patients with fatal disease were chosen as the gold spectively by case-note review of 20 cases of severe fatal vasculitis. Systemic vasculitis was diagnosed standard for severe disease. Fatal disease was characterized by high total VDI scores with multi-system according to accepted criteria, and patients were then classified according to the ACR criteria.5,10-17 damage including organ failure. In non-fatal vasculitis, multi-system damage identified a subgroup of
The Chapel Hill consensus definitions were used for microscopic polyangiitis18 and Wegener's granulpatients with the characteristics of severe disease. At last observation the VDI was a powerful measure of omatosis, which were further subdivided into classical (renal) and non-renal disease as described disease severity (Exley AR, Bacon PA, Luqmani R, et al., manuscript submitted) . Identification of early previously.19 Data from the interval after both presentation and first relapse were collected in 35 indicators of outcome and severe disease is critical for further progress in the management of systemic of the patients with non-fatal vasculitis ( Table 1) . The date of first symptoms attributable to vasculitis vasculitis. We therefore investigated the earliest features of severe disease in a serial study of 120 was recorded as the onset of disease. The date of presentation to any hospital was recorded as the patients with systemic vasculitis. We compared damage following presentation with damage followcommon reference point. We compared the increase in damage scores in the 6 months after presentation ing relapse, then examined the relationship between early and late damage. These investigations high-(interval A) with the 6 months after relapse (interval B). lighted five early clinical features of systemic vasculitis which we tested for their power to predict severe
The 100 cases with non-fatal vasculitis were grouped according to damage scored at 6 months disease and poor outcome at last observation. These studies were applied both to all patients with vasculafter presentation. Group 1 included patients with damage limited to a single organ-based system, itis and to the subgroup of patients with Wegener's granulomatosis, as an example of primary necrotizing while group 2 patients had damage in more than one organ-based system. The same criteria were systemic vasculitis.
applied to the 49 cases of Wegener's granulomatosis with non-fatal vasculitis (Table 2) .
Methods

Patients Damage scores
There are 64 items of damage listed in the VDI, This observational study was based on data from 100 patients with systemic vasculitis attending the which also incorporates a glossary and guidelines for its application. All damage occurring since the Birmingham University Hospital Vasculitis Clinics July 1993-December 1995 during prospective onset of vasculitis is included. The total VDI score is the cumulative sum of items of damage scored. follow-up studies9. Data was also collected retro- comparison of paired data, and the Mann-Whitney least one item of damage is recorded, with a max-U test for comparison between two groups. All tests imum value of 11. The critical damage score is the were two-tailed. The odds ratios for severe disease number of items of damage consistent with organ at last observation (with 95% CIs) were calculated failure, with a maximum value of 16. Treatmentfor patients with renal damage, lung damage, and related damage refers to nine items of damage damage affecting two or more organ-based systems attributable to drug toxicity. at 6 months after presentation.20 Fatal disease was used as the gold standard for severe systemic vasculitis. We found that patients with fatal disease had significantly higher total VDI Results scores, systems scores, and critical damage scores than non-fatal disease at last observation. We also Time course of damage in systemic found that damage thresholds of a total VDI score vasculitis ≥5, a systems score ≥3, and a critical damage score ≥1 in patients with systemic vasculitis were Damage occurs early, since 42/100 (42%) of patients with non-fatal vasculitis and 7/20 (35%) of patients powerful discriminators of fatal disease at last observation. A subgroup of patients with non-fatal disease with fatal vasculitis had sustained damage in the interval between first symptoms and presentation to also showed these characteristics of severe disease [Exley AR, Bacon PA, Luqmani R, et al., submitted] .
hospital ( Figure 1a ). Total VDI scores at presentation showed no difference between fatal disease and nonIn this serial study we examined whether these characteristics of severe systemic vasculitis would fatal disease, but serial assessments revealed total VDI scores were significantly higher in fatal disease discriminate between fatal and non-fatal disease when applied 2 years after presentation. Supported by 6 months after presentation (Figure 1b) . Evidence of early damage was also clear in specific disease by these data, we used damage thresholds to define severe disease in cases of non-fatal vasculitis, where groups. In non-renal Wegener's granulomatosis, total VDI scores at presentation were 1 (0-2) vs. 2 (1-3) death as the criterion for severe disease is unavailable. We then tested clinical parameters within 6 at 6 months ( p<0.001). Similarly, in microscopic polyangiitis, total VDI scores were 0 (0-2) at premonths of presentation for their power to predict severe disease at last observation. The parameters sentation vs. 3 (2-3) at 6 months ( p=0.036). During the 6 months after presentation, the increase in total tested were specific diagnosis; diagnostic subgroup, in particular classical vs. non-renal Wegener's granul-VDI scores was 2 (1-3) in fatal disease vs. 1 (0-2) in non-fatal disease ( p=0.016). At 2 years after omatosis; age at presentation; sex; renal damage at 6 months; lung damage at 6 months; and damage in presentation, total VDI scores were significantly higher in fatal disease than in non-fatal disease two or more systems at 6 months. These parameters were tested in the 100 cases of non-fatal systemic ( Figure 1c ). Multi-system damage occurred early, particularly vasculitis and the 47 cases of classical and nonrenal Wegener's granulomatosis.
in fatal vasculitis, where three patients had multi- Figure 2 . Serial systems scores in 120 patients with systemic vasculitis. The 120 patients with systemic vasculitis were assessed for damage at presentation, 6 months and Figure 1 . Serial total VDI scores in 120 patients with 2 years after presentation, using the VDI. The number of systemic vasculitis. The VDI was used to measure damage organ-based systems scoring at least one item of damage in 120 patients with systemic vasculitis at presentation, 6 was determined, and expressed as the systems score. months and 2 years after presentation. Total VDI scores Systems scores in severe fatal vasculitis (filled bars) were in severe fatal vasculitis (filled bars) were compared with compared with those for non-fatal vasculitis (open bars) non-fatal vasculitis (open bars) at presentation ( p=0.59), at presentation ( p=0.70), at 6 months ( p=0.009), and at 6 months ( p=0.02), and at 2 years ( p<0.0001). The at 2 years ( p<0.0001). Systems scores were higher in total VDI score was higher in severe fatal vasculitis at 6
severe fatal vasculitis at 6 months than at presentation months than at presentation ( p<0.001) and was higher ( p<0.001), and were higher at 2 years than at 6 months at 2 years than at 6 months ( p=0.004). The total VDI ( p<0.001). Systems scores were higher in non-fatal score was higher in non-fatal vasculitis at 6 months than vasculitis at 6 months than at presentation ( p<0.001), at presentation, ( p<0.001) and was higher at 2 years and were higher at 2 years than at 6 months than at 6 months ( p<0.001).
( p<0.001).
system damage by presentation (Figure 2a) . Serial during interval A vs. 4/35 (11%) patients during assessments revealed that systems scores had interval B, p=0.01 (Figure 3a) . The systems score increased significantly in all patients by 6 months highlighted the greater damage which occurred after after presentation (Figure 2b ). The systems score was presentation than after relapse. The median increase 3 (2-5) in fatal disease vs. 2 (1-3) in non-fatal in systems score during interval A was 1 (0-2) vs. a disease ( p<0.001) at 6 months. Systems scores were median increase of 0 (0-1) during interval B ( p= higher still by 2 years after presentation although the 0.007) (Figure 3b ). increase was less striking than within the first 6 months after presentation (Figure 2c) . At 2 years after
The characteristics of early and late damage presentation, the systems score was 4 (3-6) in fatal disease vs. 2 (1-3) in non-fatal disease (p<0.0001).
We examined all cases of non-fatal vasculitis to determine which organ-based systems had recorded We tested the observation that damage occurred early by comparing the increase in damage scores damage by 6 months after presentation (early damage). We then determined how many additional in the 6 months after presentation, interval A, with the 6 months after relapse, interval B (Table 1) . Total cases recorded damage by last observation (late damage). There were more cases with early damage VDI scores increased by ≥2 in 17/35 (49%) patients earliest clinical parameters predictive of severe disease at last observation in all cases, in non-fatal systemic vasculitis, and in patients with Wegener's granulomatosis (Table 3) . Patients with a poor outcome at last observation were not identified by the specific diagnosis within the group of systemic vasculitides, nor subdividing patients into classical and non-renal Wegener's granulomatosis, nor age at presentation nor sex. Early renal damage occured almost equally in patients with severe disease and mild/moderate disease at last observation (Table 3) . In contrast, early lung damage was between 3.5 and 4.7 times more likely in patients who had severe disease than in those with mild/moderate disease at last observation. Early damage in two or more systems was between 3.0 and 6.9 times more likely in patients who had severe disease than in those with mild/moderate disease at last observation. In Wegener's granulomatosis, early damage in two or more systems was between 2.8 and 6.9 times more likely in patients who had severe disease than in those with mild/moderate disease at last observation (Table 3 ). We further examined the value of early multipresentation and relapse. Thirty-five patients with nonsystem damage as an indicator of poor outcome by fatal systemic vasculitis who had a first relapse a median dividing patients into those in whom early damage of 2.3 years (1.5-4.2 years) after presentation were did not extend beyond a single system (group 1) assessed (see Table 1 ). Serial damage scores were measand those in whom early damage affected two or ured as total VDI scores and systems scores. The increases more systems (group 2). This approach was applied in damage scores in the 6 months after presentation to all cases of non-fatal systemic vasculitis, then all (interval A) and the 6 months after relapse (interval B) non-fatal classical and non-renal Wegener's were compared. a The increase in total VDI scores was granulomatosis. Baseline characteristics differed higher during interval A than interval B, ( p=0.01). b The increase in systems score was higher during interval A little, though cases in group 2 tended to be older than during interval B ( p=0.007).
than those in group 1. These groups were significantly different in their outcome and disease severity at last observation. Patients in group 2 had a poor than late damage in the neuropsychiatric (23 vs. 4), outcome, with significantly higher total VDI scores, renal (26 vs. 6) , pulmonary (24 vs. 17), ear, nose systems scores and critical damage scores than and throat (43 vs. 18), skin (22 vs. 10) and peripheral those in group 1, at last observation. In Wegener's vascular systems (9 vs. 4) . Early and late damage granulomatosis, patients in group 2 also had a poor were similar in the musculo-skeletal (7 vs. 8) and outcome, with significantly higher total VDI scores, ophthalmic systems (8 vs. 9) . There were fewer cases systems scores and critical damage scores than recording early than late damage in the gastrothose in group 1, at last observation (Table 4) . intestinal (1 vs. 4), cardiovascular (21 vs. 27 ) and other damage/drug toxicity systems (3 vs. 18). Treatment-related damage was unusual early in the disease, occurring in 6 patients at 6 months vs. 26 Discussion patients at last observation.
In this serial study, damage occurred early, early damage was disease-related while treatment-related
Early damage as an indicator of outcome damage was late, and damage was an early indicator of a poor outcome. This study was driven by the At 2 years after presentation, the odds ratios for fatal disease were: 12.4 (4.2-36.9) using a total VDI score need for alternative measures of outcome since death is uncommon in acute systemic vasculitis and the of ≥5, 10.5 (2.9-38.4) using a systems score of ≥3, and 8.1 (2. 5-26. 2) using a critical damage prognosis even within specific diagnostic groups is so variable. Comprehensive clinical assessment score of ≥1. These data provide further support for the value of damage thresholds and the evidence of includes parameters which characterize patients in a quantifiable and reproducible manner.4,5,8 These early damage. We then investigated which were the Wegener's 2.8 (0.8-9.7) 6.9 (1.9-25.2) 2. 8 (0.8-9. 3) granulomatosis
In 100 cases of non-fatal systemic vasculitis and 49 cases of Wegener's granulomatosis, five early clinical criteria were examined as indicators of poor outcome or severe disease at last observation defined by damage thresholds characteristic of severe fatal vasculitis. The odds ratios for severe disease at last observation (with 95% CIs) were calculated for each criteria. Neither age at presentation nor sex indicated outcome at last observation (data not shown).
clinical instruments may be more powerful than related, not due to drug toxicity, which suggests there is a therapeutic window for more aggressive laboratory indices in detecting changes in disease activity.21 We have developed clinical indices of treatment of systemic vasculitis at presentation. Therapeutic options include a shorter interval activity and damage in systemic vasculitis, the Birmingham Vasculitis Activity Score (BVAS)5 and between pulses, or higher doses of cyclophosphamide, for which there is already some experience in the Vasculitis Damage Index (VDI).8 Both the BVAS and VDI are validated, and have been adopted by vasculitis and SLE.22,23 Additional pulses of methylprednisolone and cyclophosphamide within the first the European Community Concerted Action Group for the Study of Therapeutic Trials in Systemic 4 weeks of treatment may induce remission more reliably than a regimen of monthly pulses.6,24 Delay Vasculitis (ECSYSVASTRIAL) for three core protocols in systemic vasculitis. In a cross-sectional study, we in presentation and diagnosis of systemic vasculitis hinders early treatment, which may be critical. We used fatal disease as the gold standard for severe systemic vasculitis to show that damage at last found that less damage occurred after relapse than after presentation, and yet patients undergoing observation is a powerful index of disease severity (Exley AR, Bacon PA, Luqmani R, et al., submitted) .
relapse can have disease as florid as than the initial presentation or even more active. 6 The relationship This serial study reveals that damage can occur as early as the interval between first symptoms and between disease activity and damage is complex,25 but an attractive explanation is the beneficial effects presentation to hospital, and significant renal, pulmonary, and neurological damage can accumulate of early diagnosis and treatment in patients undergoing long-term follow-up. within 6 months of presentation. Thus damage occurs early in systemic vasculitis. Early damage is disease-
The differences between early and late damage The 100 patients with non-fatal vasculitis and 49 cases of Wegener's granulomatosis were grouped according to damage scored at 6 months after presentation. Group 1 comprises patients in whom damage was limited to a single organ-based system, and group 2 those where damage affected more than one organ-based system. Damage scores at last observation were significantly higher in group 2 than in group 1, both for all patients and for the subgroup with Wegener's granulomatosis.
are not peculiar to the clinical instrument, since the surgical specimens37 and experimental techniques38 provide evidence of continuing subclinical disease VDI is sensitive to change, and second events can be scored for key items of damage.8 The later onset activity, whilst relapse is common.6 In acute leukaemia, resistant disease is identified early and treatof treatment-related damage is in agreement with previous studies reporting inflammatory, toxic and ment is rapidly escalated. In systemic vasculitis, early recourse to high-dose cyclophosphamide or exneoplastic complications of cyclophosphamide therapy. 7, 26, 27 These complications are related to dose perimental drugs39,40 may be required to minimize damage. These therapies may induce long-lasting and previous exposure, consistent with clinical experience of shrinking therapeutic margins later in remission, prevent damage, or even cure the disease,39,40 but at the cost of profound immunodisease. This re-emphasizes the importance of preventing relapse in systemic vasculitis, and clearly suppression in some patients. Strategies for reversing this immunosuppression and possibly curing these differentiating disease activity from damage or scarring which is unlikely to benefit from immunosupdiseases are currently being developed. 41 We found that damage occurs early in systemic pression.4 A proactive approach is supported by evidence that damage has important consequences vasculitis, particularly in severe disease, and that multi-system damage is an early indicator of poor for functional outcome: patients with lung damage report worse physical function and role limitation outcome. Similar observations were made in Wegener's granulomatosis as an example of primary due to physical ill-health.28
Our data here indicate that the spectrum of necrotising systemic vasculitis. Early damage should prove a valuable index of outcome in therapeutic damage within 2 years of presentation clearly differentiates fatal disease from non-fatal disease, indeed trials. These data require confirmation in prospective studies such as the ECSYSVASTRIAL studies the distinction can be made as early as 6 months after presentation. Since this early damage is diseaseunderway. The novel perspective of damage in systemic vasculitis also provides insight into alternatrelated, it may have a wider prognostic value in patients with non-fatal vasculitis. To test this hypoive strategies for the treatment of these chronic diseases and offers an approach to the investigation thesis, we used criteria for severe disease derived from the characteristics of patients with fatal disease.
of laboratory markers of disease by stratifying cases according to disease severity. If we accept a need We then showed that early lung damage, and early damage affecting two or more systems, were good for early diagnosis and new approaches to treatment, this will have important implications for the manageindices of severe disease and a poor outcome at last observation. These data indicate that the VDI is a ment of these patients at specialist centres and referring hospitals. clinical instrument that can provide an early index of outcome in systemic vasculitis, which may prove useful as surrogate end points for therapeutic trials. Damage sustained within 2 years of presentation Acknowledgements could be used to stratify patients according to disWe are grateful for the support of Dr Adu and ease severity. There are sound precedents for using clinical colleagues who referred their patients for a parameter which is not a diagnostic criterion, assessment. We thank members of the Birmingham namely damage, to stratify patients for disease severVasculitis Group, the European Community ity in order to investigate the importance of laboratory Concerted Action Group for the Study of Therapeutic parameters.29,30 Interestingly, severe alpha 1 -antitrypTrials in Systemic Vasculitis, and Dr Mulherin for sin deficiency is associated with the development of their help and advice. This work was supported in severe systemic necrotizing vasculitis with heterogenpart by the Arthritis and Rheumatism Council. ous manifestations.31 Stratifying patients by disease severity using damage may be productive in testing other genetic associations with severe systemic vasculitis.32-35 Identification of laboratory markers of
